# AGN-199201 for the Treatment of Erythema With Rosacea

> **NCT01735201** · PHASE2 · COMPLETED · sponsor: **Allergan** · enrollment: 357 (actual)

## Conditions studied

- Rosacea
- Erythema

## Interventions

- **DRUG:** AGN-199201 Dose A
- **DRUG:** AGN-199201 Dose B
- **DRUG:** AGN-199201 Dose C
- **DRUG:** AGN-199201 Vehicle

## Key facts

- **NCT ID:** NCT01735201
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2013-05
- **Final completion:** 2013-06
- **Target enrollment:** 357 (ACTUAL)
- **Last updated:** 2019-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01735201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01735201, "AGN-199201 for the Treatment of Erythema With Rosacea". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01735201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*